What Is MK-677? (Same as Ibutamoren — Full Breakdown)
MK-677 and MK 677 are the same compound. The notation variation (hyphen or space) changes nothing about the molecule. Both refer to ibutamoren mesylate, a non-peptide growth hormone secretagogue that mimics the action of ghrelin on the pituitary gland. Unlike peptide-based growth hormone secretagogues (GHRP-6, hexarelin, ipamorelin), MK-677 is orally bioavailable and has a half-life of approximately 24 hours, allowing once-daily dosing without injections. Clinical trials have demonstrated dose-dependent increases in serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, with sustained elevations lasting 24 hours per dose. A pharmacokinetic profile no natural ghrelin-binding compound replicates.
We've worked with research teams using MK-677 across metabolic studies, body composition protocols, and aging research since 2018. The confusion about naming conventions. MK-677 versus MK 677 versus ibutamoren. Creates unnecessary hesitation among researchers who assume the hyphen signifies a different analogue or formulation variant.
Is MK-677 the same as MK 677?
Yes. MK-677, MK 677, and MK677 are three notational variants for the identical chemical compound: ibutamoren mesylate, CAS number 159752-10-0. The numeric designation '677' is a developmental code from Merck, the pharmaceutical company that first synthesised the molecule in the 1990s. Whether written with a hyphen, space, or no separator, the reference is to a single non-peptide ghrelin receptor agonist with a molecular weight of 624.77 g/mol and the chemical formula C₂₇H₃₆N₄O₅S.
Most research publications use the hyphenated form (MK-677), but suppliers and study protocols vary in notation without changing the compound's identity or purity. The critical distinction is between MK-677 and actual peptide-based growth hormone secretagogues. Ibutamoren is structurally a spiropiperidine derivative, not an amino acid chain.
This article covers how MK-677 works at the receptor level, what differentiates it from peptide GH secretagogues and synthetic GH itself, typical research dosing ranges and response kinetics, and what the evidence shows about sustained use beyond 12 months.
How MK-677 Works (Mechanism of Action)
MK-677 binds selectively to the ghrelin receptor (growth hormone secretagogue receptor type 1a, or GHSR1a) located on somatotroph cells in the anterior pituitary gland. Ghrelin is the endogenous 'hunger hormone' that stimulates both appetite and GH release. Ibutamoren mimics this action with higher receptor affinity and longer duration than natural ghrelin. Once bound, the receptor activates Gq protein signalling, which triggers calcium mobilisation and stimulates pulsatile secretion of growth hormone into circulation.
Unlike exogenous recombinant human growth hormone (rhGH), which directly replaces endogenous GH and suppresses natural pulsatile secretion via negative feedback, MK-677 amplifies the body's own GH pulses without shutting down the hypothalamic-pituitary axis. Studies published in the Journal of Clinical Endocrinology & Metabolism found that 25mg daily MK-677 increased mean 24-hour GH concentrations by approximately 60% and IGF-1 levels by 40–90% depending on baseline status. Sustained across 12 months of continuous administration without tachyphylaxis.
The downstream effects cascade through IGF-1 production in the liver: increased protein synthesis in muscle tissue, enhanced lipolysis (fat breakdown) via hormone-sensitive lipase activation, improved nitrogen retention, and upregulation of satellite cell activity in skeletal muscle. What separates MK-677 from peptides is the oral bioavailability. GHRP-6 and hexarelin require subcutaneous injection because gastric acid and digestive enzymes destroy peptide bonds. Ibutamoren's non-peptide structure survives first-pass metabolism, reaching peak plasma concentration approximately 2 hours post-dose.
MK-677 vs Peptide Growth Hormone Secretagogues
| Feature | MK-677 (Ibutamoren) | Peptide GH Secretagogues (GHRP-6, Hexarelin, Ipamorelin) | Synthetic rhGH (Somatropin) |
|---|---|---|---|
| Chemical Structure | Non-peptide spiropiperidine derivative | Short-chain amino acid sequences (4–6 residues) | Recombinant 191-amino-acid polypeptide |
| Administration Route | Oral (capsule, liquid suspension) | Subcutaneous or intramuscular injection | Subcutaneous injection |
| Half-Life | Approximately 24 hours | 20–120 minutes depending on analogue | 2–4 hours (requires daily or multiple daily injections) |
| Mechanism | Ghrelin receptor agonist → endogenous GH pulse amplification | Ghrelin receptor agonist → endogenous GH pulse amplification | Direct GH replacement → suppresses natural production |
| Dosing Frequency | Once daily | 1–3 times daily (pre-meal or pre-sleep timing critical) | Daily or multiple daily |
| Effect on Natural GH Production | Preserves pulsatile secretion patterns | Preserves pulsatile secretion patterns | Suppresses endogenous GH via negative feedback loop |
| IGF-1 Elevation Magnitude | 40–90% above baseline at 25mg daily | 50–150% above baseline depending on peptide and dose | 200–400% above baseline (dose-dependent, supraphysiologic levels common) |
| Oral Bioavailability | High (survives gastric acid and first-pass metabolism) | Zero (peptide bonds degraded in stomach) | Zero |
| Research Assessment | Sustained amplification without receptor desensitisation over 12+ months documented in clinical trials | Effective but requires injection compliance; some analogues show tachyphylaxis after 8–12 weeks | Most potent GH elevation but shuts down natural axis; post-cycle recovery period required |
The practical implication: MK-677 offers the convenience of oral dosing with sustained 24-hour GH elevation, making it the preferred choice for studies requiring daily compliance without injection training. Peptides remain valuable when precise pre-meal or pre-sleep GH pulses are desired, or when researchers want to compare multiple secretagogue analogues. Synthetic rhGH is reserved for replacement therapy studies or protocols explicitly testing supraphysiologic GH exposure.
Our team has found that researchers often underestimate the compliance advantage of once-daily oral administration. Study dropout rates in protocols requiring twice-daily peptide injections run 30–40% higher than equivalent MK-677 arms over 16-week periods.
Research Dosing and Response Kinetics
Clinical trials have tested MK-677 at doses ranging from 10mg to 50mg daily, with 25mg emerging as the most commonly studied dose due to the balance between GH/IGF-1 elevation and side effect profile. A two-year study in elderly adults published in the Annals of Internal Medicine used 25mg daily and documented sustained IGF-1 increases of 72.9% at 12 months without tolerance development. Peak plasma ibutamoren concentration occurs approximately 2 hours post-dose, with GH secretion beginning within 30–60 minutes and peaking around 90–120 minutes.
The GH pulse pattern differs from fasting-induced or exercise-induced pulses: MK-677 produces a broader, more sustained elevation rather than a sharp spike. This creates a different metabolic signature. Less dramatic lipolytic signalling immediately post-dose but more consistent anabolic signalling across the 24-hour period. Studies measuring body composition changes typically observe measurable lean mass increases (1.1–2.7 kg over 8–16 weeks at 25mg daily) and fat mass reductions (0.5–1.5 kg over the same period) without dietary intervention.
Age modulates response magnitude: older adults (65+ years) show proportionally larger IGF-1 increases because baseline levels decline with age. A 25mg dose that elevates IGF-1 by 50% in a 25-year-old subject may produce a 90% increase in a 70-year-old subject with lower baseline GH secretory capacity. Dose escalation beyond 25mg produces diminishing returns. 50mg daily elevated IGF-1 only marginally higher than 25mg in head-to-head comparisons, while appetite stimulation and transient insulin resistance markers increased proportionally.
Here's what we've learned working with labs running long-duration protocols: the GH secretagogue effect is dose-responsive but not linear. Doubling the dose doesn't double the GH output. Receptor saturation kinetics plateau around 30–35mg daily for most subjects.
Key Takeaways
- MK-677, MK 677, and MK677 are three notational variants for the same compound: ibutamoren mesylate, a non-peptide ghrelin receptor agonist with a 24-hour half-life.
- Unlike peptide growth hormone secretagogues, ibutamoren is orally bioavailable and survives gastric acid degradation, allowing once-daily dosing without injections.
- Clinical trials at 25mg daily demonstrated 60% increases in mean 24-hour GH levels and 40–90% IGF-1 elevation sustained across 12 months without tachyphylaxis.
- MK-677 amplifies endogenous GH pulses without suppressing natural pituitary function. Contrasting with exogenous rhGH, which shuts down the hypothalamic-pituitary axis via negative feedback.
- Response magnitude is age-dependent: older subjects with lower baseline GH secretory capacity show proportionally larger IGF-1 increases at equivalent doses.
- The compound binds to GHSR1a receptors on pituitary somatotroph cells, triggering Gq protein signalling and calcium mobilisation that stimulates pulsatile GH secretion.
MK-677 Research Applications: What the Evidence Shows
| Research Application | Dosing Range Studied | Key Findings from Clinical Trials | Mechanism Involved |
|---|---|---|---|
| Sarcopenia and Age-Related Muscle Loss | 25mg daily for 12–24 months | Increased lean body mass by 1.1–2.7 kg; improved physical function scores in elderly adults (Annals of Internal Medicine, 2-year study) | IGF-1-mediated muscle protein synthesis; satellite cell activation; enhanced nitrogen retention |
| Bone Density and Fracture Risk | 25mg daily for 12 months | Increased bone mineral density at lumbar spine and femoral neck; elevated markers of bone formation (osteocalcin, PINP) | GH-stimulated osteoblast activity; IGF-1 promotion of bone matrix deposition |
| Sleep Quality and Recovery | 10–25mg daily for 8–16 weeks | Increased REM sleep duration by 20–50%; improved self-reported sleep quality scores | Ghrelin receptor activation influences sleep architecture via hypothalamic pathways |
| Metabolic Function and Body Composition | 25mg daily for 8–16 weeks | Reduced visceral adipose tissue; transient insulin resistance during active dosing (normalises post-cessation) | Lipolysis via hormone-sensitive lipase; temporary GH-mediated insulin antagonism |
| Appetite and Caloric Intake | 10–50mg daily | Dose-dependent increase in hunger and food intake (10–30% caloric surplus commonly reported) | Direct ghrelin receptor agonism mimics endogenous hunger signalling |
| Professional Assessment | MK-677 is the most convenient GH secretagogue for long-duration studies requiring daily compliance without injection protocols. The 24-hour half-life and oral bioavailability eliminate the adherence barriers that plague peptide-based research. Appetite stimulation is the primary tolerability concern; protocols pairing MK-677 with calorie-controlled feeding schedules show better body composition outcomes than ad libitum intake arms. |
What If: MK-677 Scenarios
What If I See 'Ibutamoren' on a Certificate of Analysis Instead of 'MK-677'?
That's correct nomenclature. Ibutamoren is the International Nonproprietary Name (INN) for the compound, while MK-677 is the developmental code. A reputable supplier will list both names on the CoA: 'Ibutamoren Mesylate (MK-677)' alongside CAS number 159752-10-0. If the CoA shows only a trade name or generic 'growth hormone secretagogue' without specifying ibutamoren or the CAS number, request clarification before proceeding. Vague labelling increases the risk of receiving a different ghrelin agonist analogue or a peptide mislabelled as MK-677.
What If the Compound Arrives as a Powder Instead of Capsules?
MK-677 is most commonly supplied as ibutamoren mesylate salt in powder form for research applications, requiring reconstitution in a sterile suspension medium before dosing. This is standard for high-purity research-grade material. Powder form allows precise dosing control and avoids fillers or binders present in pre-made capsules. Reconstitute using bacteriostatic water, sterile saline, or polyethylene glycol 400 (PEG-400) depending on your protocol's administration route. Store reconstituted solutions refrigerated at 2–8°C and use within 30 days to maintain compound stability.
What If GH or IGF-1 Levels Don't Increase as Expected?
Dose timing, baseline GH status, and assay methodology all influence measured response. First, verify dosing occurred on an empty stomach or with a non-protein meal. Dietary protein triggers endogenous GH suppression via insulin and amino acid signalling, which can blunt MK-677's effect if dosed immediately post-meal. Second, confirm the assay measures total IGF-1, not free IGF-1. MK-677 increases total IGF-1 but doesn't necessarily alter IGF-binding protein ratios. Third, check baseline GH secretory capacity: subjects with already-elevated GH (young athletes, fasted states) show smaller percentage increases than older or GH-deficient populations. If all variables check out and response remains minimal, suspect compound purity or degradation during storage. Request a replacement batch and independent third-party testing.
The Unvarnished Truth About MK-677
Here's the honest answer: MK-677 won't replicate the muscle-building effects of exogenous growth hormone at supraphysiologic doses. The IGF-1 elevations are meaningful. 40–90% above baseline is clinically significant for bone density, sleep quality, and lean mass preservation. But they're not the 200–400% spikes that synthetic GH produces. Researchers expecting dramatic body recomposition in 8 weeks will be disappointed. What MK-677 does deliver is sustained, physiologic-range GH amplification without injections and without shutting down natural production. That's valuable for long-duration studies, elderly populations, and protocols where compliance is the limiting factor. But it's not a shortcut to the outcomes rhGH produces in young, healthy subjects.
The appetite stimulation is real and dose-dependent. Subjects on 25mg daily report 10–30% increases in caloric intake if food access is unrestricted. Pair MK-677 with ad libitum feeding and you'll see fat gain alongside lean mass gains. Controlled feeding protocols or appetite-management co-interventions are necessary if body composition improvement is the endpoint.
At Real Peptides, every batch of MK-677 undergoes third-party HPLC verification before release. You're not working with relabelled peptides or ambiguous 'growth hormone support' blends. When notation matters less than purity, exact amino-acid sequencing and verifiable CAS numbers matter more. You can explore our commitment to precision across compounds like Hexarelin and CJC-1295/Ipamorelin. Every research-grade peptide we supply meets the same standard.
The notation you use. MK-677, MK 677, or ibutamoren. Changes nothing about the molecule's structure or function. What changes outcomes is compound purity, dosing consistency, and realistic expectations about what a ghrelin receptor agonist can achieve versus what synthetic GH delivers. Know the difference, design your protocol accordingly, and the confusion over hyphenation becomes irrelevant.
Frequently Asked Questions
Is MK-677 the same compound as MK 677 or are they different analogues?
▼
MK-677 and MK 677 are identical — the hyphen versus space notation is stylistic preference, not a chemical distinction. Both refer to ibutamoren mesylate, CAS number 159752-10-0, a non-peptide ghrelin receptor agonist. Research publications typically use the hyphenated form, but suppliers and study protocols vary without altering the compound’s identity or purity.
How does MK-677 differ from peptide-based growth hormone secretagogues like GHRP-6 or ipamorelin?
▼
MK-677 is a small-molecule spiropiperidine derivative with oral bioavailability and a 24-hour half-life, allowing once-daily dosing without injections. Peptide secretagogues (GHRP-6, hexarelin, ipamorelin) are short amino acid chains requiring subcutaneous injection because gastric acid destroys peptide bonds. Both classes bind ghrelin receptors and amplify endogenous GH pulses, but MK-677’s non-peptide structure survives first-pass metabolism, creating a compliance advantage in long-duration research protocols.
What is the typical research dosing range for MK-677 and how long does it take to see IGF-1 increases?
▼
Clinical trials most commonly use 25mg daily, with doses ranging from 10mg to 50mg tested in published studies. IGF-1 elevation begins within 7–10 days of daily dosing, reaching steady-state increases of 40–90% above baseline by week 4. Peak plasma concentration occurs approximately 2 hours post-dose, with GH secretion beginning within 30–60 minutes. Studies in elderly adults documented sustained IGF-1 elevations across 12–24 months without tolerance development.
Does MK-677 suppress natural growth hormone production like exogenous rhGH does?
▼
No — MK-677 amplifies endogenous GH pulses by stimulating ghrelin receptors on pituitary somatotroph cells without triggering negative feedback suppression. This contrasts with exogenous recombinant human growth hormone (rhGH), which directly replaces natural GH and shuts down the hypothalamic-pituitary axis. Clinical data show MK-677 preserves pulsatile GH secretion patterns even during continuous long-term administration.
What side effects should researchers expect when subjects use MK-677?
▼
The most common side effect is dose-dependent appetite stimulation — subjects on 25mg daily report 10–30% increases in caloric intake if food access is unrestricted. Transient increases in fasting glucose and insulin resistance markers occur during active dosing but normalise post-cessation. Some subjects report water retention (peripheral oedema) and mild lethargy during the first 2–4 weeks, which typically resolves with continued use. Serious adverse events are rare in published trials at standard research doses.
Can MK-677 be taken with food or does it need to be dosed on an empty stomach?
▼
Dosing on an empty stomach or with a non-protein meal maximises GH response — dietary protein triggers insulin and amino acid signalling that suppresses endogenous GH secretion, potentially blunting MK-677’s effect. Clinical trials typically administered doses in the morning fasted or in the evening 2–3 hours post-meal. Oral bioavailability remains high regardless of food intake, but GH pulse amplitude is optimised when insulin levels are low.
How does age affect response to MK-677 — do older subjects respond differently than younger ones?
▼
Yes — older adults show proportionally larger IGF-1 increases because baseline GH secretory capacity declines with age. A 25mg dose that elevates IGF-1 by 50% in a 25-year-old subject may produce a 90% increase in a 70-year-old subject with lower baseline levels. This is why most published geriatric studies (sarcopenia, bone density, frailty) use MK-677 — the compound compensates for age-related GH decline without requiring supraphysiologic dosing.
What is the difference between MK-677 and actual synthetic growth hormone injections?
▼
MK-677 stimulates the body’s own GH production by binding ghrelin receptors, producing physiologic-range elevations (40–90% above baseline IGF-1). Synthetic rhGH is direct hormone replacement that bypasses natural regulation, producing supraphysiologic elevations (200–400% above baseline) but suppressing endogenous GH via negative feedback. MK-677 is orally bioavailable and preserves pituitary function; rhGH requires injection and shuts down natural secretion. The magnitude of anabolic effects differs proportionally — rhGH produces larger body composition changes but at the cost of axis suppression.
How should MK-677 powder be stored and reconstituted for research use?
▼
Store lyophilised MK-677 powder at −20°C in a sealed container protected from light and moisture. Reconstitute using bacteriostatic water, sterile saline, or polyethylene glycol 400 (PEG-400) depending on your protocol’s administration route. Once reconstituted, refrigerate the solution at 2–8°C and use within 30 days to maintain compound stability. Avoid repeated freeze-thaw cycles — aliquot reconstituted solutions into single-use volumes if long-term storage is required.
Why do some suppliers call it ‘ibutamoren’ while others use ‘MK-677’ — are these different products?
▼
No — ibutamoren is the International Nonproprietary Name (INN) assigned to the compound, while MK-677 is the developmental code from Merck’s original synthesis work. Reputable suppliers list both names on Certificates of Analysis: ‘Ibutamoren Mesylate (MK-677)’ with CAS number 159752-10-0. The nomenclature difference reflects regulatory versus commercial naming conventions, not different chemical entities.
What happens if you stop taking MK-677 after several months — do GH and IGF-1 levels crash?
▼
No — because MK-677 amplifies endogenous GH pulses rather than replacing them, cessation doesn’t trigger rebound suppression. GH and IGF-1 levels return to baseline within 7–14 days post-cessation as the compound clears (24-hour half-life means >99% elimination within 5 days). This differs from stopping exogenous rhGH, which can cause temporary hypogonadotropic states requiring recovery periods. Studies show no adverse endocrine rebound effects after discontinuing MK-677, even following 24 months of continuous use.
Can MK-677 improve sleep quality or is that effect anecdotal?
▼
Clinical data support sleep architecture improvements — a study published in the Journal of Clinical Endocrinology & Metabolism found 25mg daily MK-677 increased REM sleep duration by approximately 50% and improved sleep quality scores in elderly subjects. The mechanism involves ghrelin receptor activation influencing hypothalamic sleep-wake regulation. Younger subjects with normal sleep patterns show smaller but measurable improvements in sleep continuity and slow-wave sleep stages.
